CLEVELAND, July 18, 2018 (GLOBE NEWSWIRE) -- Innovest Global Inc. (OTC Pink Current:IVST) (the “Company” or “Innovest”), a diversified holding company with operations in commercial and industrial products and services, launched its anticipated Biotechnology & Health Services Division today with the acquisition of a twenty percent interest in StemVax Therapeutics, a Translational Biotechnology Company that is currently developing a cancer vaccine therapy that enhances the patient’s immune response against brain tumors.
StemVax Glioblast (SVX-GB) is a cancer vaccine, which is a medication that stimulates or restores the immune system’s ability to fight an existing cancer by strengthening the body’s natural defenses against the cancer cells. It is a meaningful technology, which could significantly improve the quality of life and prognosis for the many people who suffer from brain tumors.
Different than Innovest’s wholly owned operating companies , the StemVax business model is one that enables Innovest to have a stake in potentially valuable intellectual property, which StemVax will attempt to proliferate by licensing to well established health research organizations experienced with taking such products to market.
Dr. Dwain Morris-Irvin, President of Innovest’s new Biotechnology & Health Services Division, founded StemVax in 2014, and is its Chief Science Officer. “I am extremely excited to be launching this Division. We have spent a lot of time working to ensure it has the elements we feel will best position it for success, and starting with StemVax is very exciting,” said Dr. Morris-Irvin. Dan Martin, CEO of Innovest Global echoed those comments and added, “Scientists and health professionals face difficult and unique challenges when considering how to advance their efforts in a commercial environment. Our Biotechnology & Health Services Division, under Dwain’s leadership, is the perfect bridge. StemVax has remarkable technology that has the potential to achieve breakthrough results for patients and is the perfect starting point.”
More about Dr. Morris-Irvin: Dr. Morris-Irvin’s PhD is in Pharmacology and Developmental Neuroscience with an emphasis on neural stem cell fate and differentiation. His research focused on neural development and Notch Signaling in mammalian neural stem cells. He also worked as an NIH/NINDS Post-Doctoral Fellow in Dr. Anders Bjorklund laboratory in Lund, Sweden. There, his focus was on research projects that investigated the potential role of cell replacement therapy for patients with Parkinson’s disease. They developed several protocols for the efficient generation of dopaminergic neurons from forebrain and ventral midbrain stem and progenitor cells. Additionally, Dr. Morris-Irvin led research investigations in the role of adaptive immunity in Parkinson’s disease. He also developed two patents in the area of immunotherapy for brain tumor patients, specifically Glioblastoma Multiforme (GBM). His research team focused on molecular mechanisms that impart therapeutic resistance in cancer cells, including cancer stem cells. They utilized this data to develop novel immunotherapies for brain tumor patients.
About Innovest Global, Inc.
Innovest Global, Inc. (OTC Markets: IVST ) is in the Conglomerates industry, a diversified holding company with operations in commercial and industrial products and services, energy, biotechnology, and health services. Innovest Global utilizes novel technology and marketing to efficiently acquire customers. Our primary growth strategy is to acquire existing companies in a select few industries, and attract new customers in cost effective ways. Currently, we have a Commercial & Industrial Division, and a Biotechnology & Health Services Division.
For more information, please visit: http://www.innovestglobal.com , and follow us on Twitter @innovestglobal .
Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts included in this press release are forward-looking statements. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company's control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Such risks, uncertainties and other factors, which could impact the Company and the forward-looking statements contained herein are included in the Company's filings with the OTC Markets. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Contact Information Corporate Office: (216) 815-1122 info@innovestglobal.com Twitter @innovestglobal
Investor Relations: Hayden IR (917) 658-7878 hart@haydenir.com
